NSTK · 01.2026Independent supplement reference
NutriStack
Edition 1.0Updated July 13, 2026

Levodopa/Carbidopa

Prescription ·Exploratory record · not publication-reviewed ·Updated July 13, 2026

Levodopa/carbidopa is the gold-standard treatment for Parkinson's disease. Levodopa is the metabolic precursor to dopamine and crosses the blood-brain barrier, where it is converted to dopamine by aromatic L-amino acid decarboxylase. Carbidopa inhibits this enzyme peripherally, reducing nausea and increasing CNS levodopa availability. Nearly all Parkinson's patients will eventually require levodopa therapy.

Evidence tier
Strong
Indexed sources
10 2016–2025
Interactions
0
Depletes
3 nutrients
Read the sources → Compare profiles
Publication status

Exploratory record, not a reviewed medical publication.

See the editorial and medical-review policies for the publication gate.

This generated database record has not completed a claim-level review by a qualified human medical reviewer. Bibliography links and evidence labels are not approval. The page remains available for reference and is excluded from search indexing.

In short

What the research says.

A quick, data-only summary. The full evidence, dosing, and sources are below.

Levodopa/carbidopa is the gold-standard treatment for Parkinson's disease. NutriStack rates the supporting evidence as strong. Common adult dosing is 25/100 mg (carbidopa/levodopa) three times daily initially, titrated to 200-800 mg levodopa/day in divided doses (as prescribed by your physician), though a prescriber sets the actual dose. With long-term use it can deplete vitamin b6, vitamin b12, folate. This profile indexes 10 sources.

What it's good for
  • Most effective medication for motor symptoms of Parkinson's disease
  • Improves bradykinesia, rigidity, and tremor
  • Rapid symptom relief
  • Available in multiple formulations (immediate, controlled, intestinal gel)
What to watch for
  • Nausea and vomiting (especially early in treatment)
  • Orthostatic hypotension
  • Dyskinesias (involuntary movements, with chronic use)
  • Concurrent use with non-selective MAO inhibitors (hypertensive crisis risk); MAO-B inhibitors are safe
  • Narrow-angle glaucoma

The bottom line

Evidence rating strong. Most-documented uses: most effective medication for motor symptoms of parkinson's disease, improves bradykinesia, rigidity, and tremor, rapid symptom relief. 10 sources indexed (2016–2025), with 0 interaction records on file.

The science

How it works, mechanistically.

Core mechanism

Levodopa is converted to dopamine in the CNS by DOPA decarboxylase, replenishing depleted dopamine in the striatum of patients with Parkinson's disease. Carbidopa inhibits peripheral DOPA decarboxylase, preventing premature conversion of levodopa to dopamine outside the brain, thereby increasing CNS bioavailability from ~1% to ~10% and reducing peripheral dopaminergic side effects (nausea, cardiovascular effects).1,2

Class
Dopaminergic / Antiparkinson
Absorption
Best on an empty stomach
Dosing

Dosing & protocol.

Common range
25/100 mg (carbidopa/levodopa) three times daily initially, titrated to 200-800 mg levodopa/day in divided doses (as prescribed by your physician)
Recommended form
Immediate-release tablets; controlled-release (Sinemet CR) for motor fluctuations; intestinal gel (Duopa) for advanced disease

Take on empty stomach 30-60 min before meals; protein can reduce absorption by competing for amino acid transporters in the gut and at the blood-brain barrier. Low-protein meals during the day may optimize 'on' time.9,10

Depletions

What it depletes.

Nutrients this medication can lower over time, and what to replace.

Vitamin B6

Moderate

Carbidopa can bind pyridoxal phosphate and reduce functional vitamin B6 availability during chronic levodopa-carbidopa therapy.

Replace Pyridoxine only with prescriber guidanceMonitor Plasma PLP + neurologic symptomsOnset Usually with high-dose or prolonged therapy

Vitamin B12

Mild

Levodopa methylation increases homocysteine burden, and low B12 status can worsen this metabolic effect during chronic therapy.

Replace MethylcobalaminMonitor Serum B12 + methylmalonic acid + homocysteineOnset Usually over months to years of therapy

Folate

Mild

Levodopa methylation can increase methyl-donor demand, making folate status clinically relevant when homocysteine rises on chronic therapy.

Replace Folate per clinician guidanceMonitor Serum folate or RBC folate + homocysteineOnset Usually over months to years of therapy

Full Levodopa/Carbidopa depletion and interaction guide →

Safety

Full safety detail.

Side effects

  • Nausea and vomiting (especially early in treatment)
  • Orthostatic hypotension
  • Dyskinesias (involuntary movements, with chronic use)
  • Motor fluctuations ('wearing off' and 'on-off' phenomena)
  • Vivid dreams and hallucinations
  • Impulse control disorders (less common than dopamine agonists)
  • Darkening of urine and sweat

Contraindications

  • Concurrent use with non-selective MAO inhibitors (hypertensive crisis risk); MAO-B inhibitors are safe
  • Narrow-angle glaucoma
  • Known hypersensitivity to levodopa or carbidopa1,2
  • History of melanoma (theoretical concern, controversial)
Sources

Sources, by evidence tier.

Numbered references. Citations throughout the page link here.

Meta-analyses & systematic reviews

4

Randomized controlled trials

1

Reference material

5
FAQ

Common questions.

Quick answers about Levodopa/Carbidopa, drawn from the data on this page.

What is Levodopa/Carbidopa?

Levodopa/carbidopa is the gold-standard treatment for Parkinson's disease. Levodopa is the metabolic precursor to dopamine and crosses the blood-brain barrier, where it is converted to dopamine by aromatic L-amino acid decarboxylase. Carbidopa inhibits this enzyme peripherally, reducing nausea and increasing CNS levodopa availability. Nearly all Parkinson's patients will eventually require levodopa therapy.

What is Levodopa/Carbidopa used for?

Commonly cited benefits of Levodopa/Carbidopa include: Most effective medication for motor symptoms of Parkinson's disease; Improves bradykinesia, rigidity, and tremor; Rapid symptom relief; Available in multiple formulations (immediate, controlled, intestinal gel). NutriStack rates the overall evidence as strong.

What is a typical dose of Levodopa/Carbidopa?

A typical adult dose of Levodopa/Carbidopa is 25/100 mg (carbidopa/levodopa) three times daily initially, titrated to 200-800 mg levodopa/day in divided doses (as prescribed by your physician). The commonly recommended form is Immediate-release tablets; controlled-release (Sinemet CR) for motor fluctuations; intestinal gel (Duopa) for advanced disease. These are general ranges, not personalized advice; confirm the right dose with a clinician.

What are the side effects of Levodopa/Carbidopa?

Reported side effects include nausea and vomiting (especially early in treatment), orthostatic hypotension, dyskinesias (involuntary movements, with chronic use), motor fluctuations ('wearing off' and 'on-off' phenomena), vivid dreams and hallucinations, impulse control disorders (less common than dopamine agonists). This is educational information; check with a healthcare professional before use.

How strong is the evidence for Levodopa/Carbidopa?

NutriStack rates this as Strong, meaning multiple high-quality meta-analyses or systematic reviews converge on the same finding. Full tier criteria are at https://nutristackapp.com/methodology/evidence-tiers.

Use this with your stack

Levodopa/Carbidopa in NutriStack.

Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.

Download on the App Store → Read the methodology

NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.